Join
Live feed
·
PRReleasevia Quantisnow
OptiNose Inc. logo

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

ByQuantisnow·Wall Street's wire, on your screen.
OPTN· OptiNose Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OPTN (OptiNose Inc.) and more on Quantisnow.